Skip to main content

*As evidenced by ARR, MRI (Gd+ T1 and T2 lesions), and 3- and 6-month CDP.1 
Actual patient taking KESIMPTA who was compensated for time. Individual results may vary.

I’m glad I started RMS treatment with KESIMPTA

Actual patient taking KESIMPTA who was compensated for time. Individual results may vary.

Alongside KESIMPTA is here to support your patients
 80% of commercial patients receive their first bridge dose in 5 days2

Based on prescription data collected from April to September 2023.

your eligible, commercially insured patients pay as little as  a $0‡ copay

Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Patients with commercial insurance and an initial denial of coverage may receive up to 12 months of free product while coverage is pursued. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at start.kesimpta.com.

ARR, annualized relapse rate; CDP, confirmed disability progression; Gd+, gadolinium-enhancing; MOA, mechanism of action; MRI, magnetic resonance imaging; MS, multiple sclerosis; RMS, relapsing multiple sclerosis.

IMPORTANT SAFETY INFORMATION

Contraindication: KESIMPTA is contraindicated in patients with active hepatitis B virus infection.

WARNINGS AND PRECAUTIONS

Infections: An increased risk of infections has been observed with other anti-CD20 B-cell depleting therapies. KESIMPTA has the potential for an increased risk of infections including serious bacterial, fungal, and new or reactivated viral infections; some have been fatal in patients treated with other anti-CD20 antibodies...

INDICATION

KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
CoverMyMeds is a registered trademark of CoverMyMeds, LLC.
References: 1. Kesimpta. Prescribing information. Novartis Pharmaceuticals Corp 2. Data on file. Injection time. Novartis Pharmaceuticals Corp; East Hanover, NJ. June 2020. 3. Data on file. Program data. Novartis Pharmaceuticals Corp; East Hanover, NJ. November 2023.